Skip to main content
DCOY
NASDAQ Life Sciences

Decoy Therapeutics Reports Going Concern Doubt, Multiple Reverse Splits, and Deeply Discounted Financing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$6.143
Mkt Cap
$3.474M
52W Low
$5.94
52W High
$415.8
52W Position info
3.4% above low
Off High info
99% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

DCOY is trading near its 52-week low of $5.94 (3.4% above the low) on light trading volume (0.2× avg).

Summary

Decoy Therapeutics Inc. reported substantial doubt about its ability to continue as a going concern, following two reverse stock splits and highly dilutive financing rounds to maintain its Nasdaq listing and fund preclinical operations.


Key Events · Legal and Risk Events · DCOY

  • Going Concern Warning Issued

    The company's independent auditors have expressed substantial doubt about its ability to continue as a going concern, highlighting significant financial challenges.

  • Multiple Reverse Stock Splits Implemented

    Decoy Therapeutics executed a 1-for-15 reverse stock split in August 2025 and a 1-for-12 reverse stock split in March 2026 to boost its share price and regain Nasdaq compliance.

  • Nasdaq Delisting Threat Resolved

    The company successfully regained compliance with Nasdaq's minimum bid price requirement on March 20, 2026, following the reverse stock splits, averting immediate delisting.

  • Highly Dilutive Financings Completed

    A November 2025 public offering raised $6.3 million in net proceeds, with an effective price of $1.50 per unit (post-March 2026 reverse split), significantly below the current market price. An additional $4.8 million was raised through an equity line of credit.


Analysis · DCOY · Life Sciences

Decoy Therapeutics Inc. has disclosed substantial doubt about its ability to continue as a going concern, a critical warning from its independent auditors. This comes after the company executed two reverse stock splits (1-for-15 in August 2025 and 1-for-12 in March 2026) to maintain its Nasdaq listing, successfully regaining compliance on March 20, 2026. The company also completed highly dilutive financing rounds, including a November 2025 offering that raised $6.3 million in net proceeds by issuing common stock and warrants. When adjusted for the subsequent 1-for-12 reverse split, the effective offering price of $1.50 per unit was significantly below the current stock price of $6.14, indicating severe financial distress. Additionally, the company sold $4.8 million in shares through an equity line of credit. These capital raises, while necessary for survival, have resulted in substantial dilution for existing shareholders. The company, a preclinical-stage biotechnology firm, continues to incur significant operating losses, with net loss increasing to $12.5 million in 2025 from $5.6 million in 2024, primarily due to increased R&D expenses from a recent merger. The stock is currently trading near its 52-week low, reflecting investor apprehension about its long-term viability despite its preclinical pipeline.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DCOY was trading at $6.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $5.94 to $415.80. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DCOY - Latest Insights

DCOY
Nov 13, 2026, 4:45 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $0.9752
Real-time Price: $0.890 info
Change: -$0.0852 (-9%) info
Market Cap: $2.123M info
DCOY
Nov 12, 2026, 6:31 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.06
Real-time Price: $0.890 info
Change: -$0.165 (-16%) info
Market Cap: $2.123M info
DCOY
Nov 12, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.06
Real-time Price: $0.890 info
Change: -$0.165 (-16%) info
Market Cap: $2.123M info
DCOY
Oct 16, 2026, 4:07 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $1.17
Real-time Price: $0.890 info
Change: -$0.280 (-24%) info
Market Cap: $2.123M info
DCOY
Oct 07, 2026, 4:59 PM EDT
Filing Type: S-1
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $0.890 info
Change: -$0.7086 (-44%) info
Market Cap: $2.123M info